• CEL-SCI posted a net loss of USD 5.7 million for the quarter ended June 30, 2026; basic and diluted loss per share narrowed to USD 0.47.
• Research and development expense edged down to USD 3.6 million; general and administrative costs rose to USD 1.9 million.
• Operating cash outflow totaled USD 4 million; gross proceeds of about USD 9.7 million were raised during the quarter.
• Plans to start global enrollment in a 212-patient FDA confirmatory registration study for Multikine; early pre-surgical tumor responses may support accelerated approval.
• Entered a partnership with Amarox to seek Saudi approval and commercialization of Multikine, with a 50/50 net revenue split.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260817887056) on August 17, 2026, and is solely responsible for the information contained therein.